For the roughly 50 million American women navigating perimenopause and menopause, the clinical pathway has long been a series of dead ends and dismissals. Primary care physicians often lack the training, while OB/GYNs can be booked months out, leaving symptoms like hot flashes, brain fog, and sleep disruption to be managed in isolation or not at all. Midi Health, a virtual clinic founded in 2021, is structuring its entire business around that specific, underserved patient population, with a model that hinges on a simple but powerful premise: this care should be covered by insurance.
Its approach is a classic wedge. By focusing exclusively on midlife hormonal health, Midi trains its clinicians to a specialized standard and contracts directly with payers. Patients, whether accessing care through an employer benefit, a health system partnership, or directly online, typically pay only a copay. This moves the model away from the cash-pay concierge care that characterizes some digital health plays and towards a utility-like, integrated layer of the healthcare system. The company reported a $1 billion valuation in 2026, following a $100 million Series D round led by Goodwater Capital [FierceHealthcare].
The insurance-covered wedge
Midi’s core product is a virtual clinic offering telehealth visits, personalized care plans, lab testing, and prescriptions, including hormone therapy and non-hormonal options [joinmidi.com]. The company says it is available in all 50 states for employer benefits and direct patient booking [PR Newswire, January 2024]. Crucially, it emphasizes that care is “insurance-covered,” having inked contracts with major national insurers to process visits as specialist appointments.
This payer strategy is central to its growth thesis. By aligning reimbursement with traditional healthcare economics, Midi aims for broader adoption than out-of-pocket models can achieve. Its distribution is multi-channel:
- Employer benefits. Positioned as a tool for retention and productivity for a large segment of the workforce.
- Health system partnerships. Integrated with providers like Memorial Hermann Health System to extend their women’s health offerings [Memorial Hermann, October 2023].
- Direct-to-consumer. Patients can book visits directly through its website.
Building a defensible clinical network
With over $100 million in total disclosed funding, Midi has aggressively scaled its clinical operations. Headcount has grown from an estimated 275 to approximately 652 employees as of April 2026 [ZoomInfo] [LeadIQ, April 2026]. This growth fuels a dedicated network of clinicians who receive specialized training in menopause care, a credential the company leverages as a quality differentiator.
The leadership team brings a mix of clinical and operational heft. CEO Joanna Strober previously founded Kurbo Health, a digital health company focused on pediatric weight management that was acquired by WW (formerly Weight Watchers) in 2018 [1843 Capital]. Co-founder and Chief Medical Officer Dr. Ariel D. N. Harlev is a board-certified OB/GYN and reproductive endocrinologist [Avestria Ventures]. This combination of a founder with a prior exit and deep clinical leadership provides a credible foundation for navigating the regulated healthcare landscape.
The AI and longevity expansion
Beyond the core clinic, Midi is investing in technology to scale and deepen its impact. The company is developing an AI-powered clinical decision support tool and a specialized women’s health search engine, using proceeds from its Series C funding [Sacra]. According to reports, it is building an internal AI chatbot to reshape clinician workflows and training, aiming to standardize and scale the nuanced care required for menopause [Business Insider, April 2026].
It has also launched a “longevity” arm, a natural extension from managing menopause symptoms to supporting the broader health and aging concerns of women over 40 [Fortune, May 2025]. This move signals an ambition to own the longitudinal health relationship for this demographic, using the menopause wedge as the entry point.
A crowded field and execution risks
The market Midi is targeting is large and historically overlooked, but it is no longer a secret. The competitive set includes well-funded players like Maven Clinic, Evernow, and Peppy. Success will depend on Midi’s ability to execute on several challenging fronts simultaneously.
- Payer depth and persistence. Maintaining and expanding favorable insurance contracts is a continuous operational hurdle. Any shift in reimbursement policy could pressure the model.
- Clinical quality at scale. As the clinician network grows, ensuring consistent, high-quality care across hundreds of providers is a non-trivial task. The AI tools are a bet on solving this, but they are not yet proven at this scale.
- Differentiation in a boom. The women’s health tech space is attracting significant capital. Midi’s focus on insurance integration is a strong moat, but competitors are pursuing similar strategies.
The company’s recent funding and valuation suggest investors believe its integrated, insurance-first approach can win. The next twelve months will be about proving that the clinical and technological infrastructure can grow as fast as the market opportunity.
For patients, the standard of care today for perimenopause and menopause remains fragmented. Many women cycle through multiple providers before finding one who takes their symptoms seriously and is knowledgeable about treatment options, which can include lifestyle changes, non-hormonal medications, and hormone replacement therapy. Access is often gated by geography, cost, and long wait times. Midi Health is betting that a national, virtual, specialized clinic,treating this life stage not as a niche but as a central healthcare need,can rewrite that pathway for millions.
Funding trajectory
The company's rapid capital accumulation underscores investor conviction in its model.
2022 Seed | 14 | M USD
2023 Series A | 25 | M USD
2024 Series B | 60 | M USD
2025 Series C | 50 | M USD
2026 Series D | 100 | M USD
Sources
- [PR Newswire, January 2024] Midi Health announces 50-state availability for employers | https://www.prnewswire.com/news-releases/midi-health-announces-50-state-availability-for-employers-301970261.html
- [joinmidi.com, Unknown] Midi Health website | https://www.joinmidi.com
- [FierceHealthcare, Unknown] Women's health clinic Midi Health closes $100M series D | https://www.fiercehealthcare.com/health-tech/womens-health-clinic-midi-health-closes-100m-series-d-round-hitting-1b-valuation
- [Memorial Hermann, October 2023] Memorial Hermann collaboration announcement | https://www.memorialhermann.org
- [ZoomInfo, Unknown] Midi Health company profile | https://www.zoominfo.com/c/midi-health/566132142
- [LeadIQ, April 2026] Midi Health employee data | https://www.leadiq.com
- [1843 Capital, Unknown] Joanna Strober profile | https://1843capital.com/joins-1843-capital-as-partner/
- [Avestria Ventures, Unknown] Dr. Ariel D. N. Harlev profile | https://www.avestria.vc/midi-health
- [Sacra, Unknown] Midi Health company analysis | https://sacra.com/c/midi-health
- [Business Insider, April 2026] How Midi Health is using AI to transform care | https://www.businessinsider.com/how-midi-health-is-using-ai-to-transform-care-scale-2026-4
- [Fortune, May 2025] Midi Health launches longevity arm | https://fortune.com
- [PR Newswire, April 2024] Midi Health raises $60M Series B | https://www.prnewswire.com/news-releases/midi-health-the-fastest-growing-virtual-clinic-for-perimenopause-and-menopause-raises-an-additional-60m-in-series-b-round--100m-total-funding-to-date--to-transform-womens-healthcare-302125839.html